Igor Bilinsky
Chief Operating Officer bei IOVANCE BIOTHERAPEUTICS, INC.
Vermögen: 563 545 $ am 31.03.2024
Profil
Igor P. Bilinsky hat die Position des Chief Operating Officer von Iovance Biotherapeutics, Inc. inne. Dr. Bilinsky hatte zuvor die Position des Chief Executive Officer bei Androclus Therapeutics, Inc. inne, die Position des VP-Business Development & Special Operations bei Halozyme Therapeutics, Inc. die Position des Principal bei The Boston Consulting Group, Inc. die Position des Chief Business Officer bei Oncternal Therapeutics, Inc, Chief Operating Officer & Senior Vice President bei AmpliPhi Biosciences Corp, Head-Research & Development bei Symyx Technologies, Inc., Senior Vice President-Corporate Development bei Vical, Inc. und Senior VP-Special Operations, GM-Immuno & Oncology bei Ignyta, Inc. Igor P. Bilinsky erhielt einen Bachelor-Abschluss vom Moskauer Institut für Physik und Technologie und einen Doktortitel vom Massachusetts Institute of Technology.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
15.04.2024 | 38 026 ( 0,01% ) | 563 545 $ | 31.03.2024 |
Aktive Positionen von Igor Bilinsky
Unternehmen | Position | Beginn |
---|---|---|
IOVANCE BIOTHERAPEUTICS, INC. | Chief Operating Officer | 15.03.2021 |
Ehemalige bekannte Positionen von Igor Bilinsky
Unternehmen | Position | Ende |
---|---|---|
ONCTERNAL THERAPEUTICS, INC. | Corporate Officer/Principal | 01.03.2021 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Chief Operating Officer | 14.01.2019 |
IGNYTA INC | Corporate Officer/Principal | 01.01.2017 |
HALOZYME THERAPEUTICS, INC. | Corporate Officer/Principal | 01.01.2010 |
Androclus Therapeutics, Inc. | Chief Executive Officer | 01.01.2007 |
Ausbildung von Igor Bilinsky
Massachusetts Institute of Technology | Doctorate Degree |
Moscow Institute of Physics & Technology | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
HALOZYME THERAPEUTICS, INC. | Health Technology |
IOVANCE BIOTHERAPEUTICS, INC. | Health Technology |
ONCTERNAL THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 6 |
---|---|
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Health Technology |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Health Technology |
Symyx Technologies, Inc.
Symyx Technologies, Inc. Packaged SoftwareTechnology Services Symyx Technologies, Inc. develops and applies high-throughput experimentation to the discovery of materials for chemical and petrochemical, pharmaceutical development, electronics, consumer goods and automotive customers. The company works together with companies seeking to transform their search for better products and processes through research collaborations and Discovery Tools sales and the license of materials, intellectual property and software. The company was incorporated in February 1999 and is headquartered in Sunnyvale, CA. | Technology Services |
The Boston Consulting Group, Inc.
The Boston Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services The Boston Consulting Group, Inc. engages in the provision of management consulting services. It specializes in automotive and mobility; biopharmaceuticals; consumer products; education; oil and gas; power and utilities; engineered products and infrastructure; financial institutions; and health care payers, providers, and services. It offers big data and advanced analytics; change management; client learning and enablement; and corporate development and financial services. The company was founded by Bruce Doolin Henderson in 1963 and is headquartered in Boston, MA. | Commercial Services |
Androclus Therapeutics, Inc. | |
Ignyta, Inc.
Ignyta, Inc. BiotechnologyHealth Technology Ignyta, Inc. operates as a medicine biotechnology company. The firm engages in the discovering, acquiring, developing and commercializing targeted new drugs for cancer patients. The company was founded by Jonathan E. Lim on September 13, 2011 and is headquartered in South San Francisco, CA. | Health Technology |